Q2 2014 Investor Conference Call on 2014-07-30 Presentation Charts

  • 266 views
Uploaded on

Presentation Charts for Q2 2014 Investor Conference Call on 2014-07-30

Presentation Charts for Q2 2014 Investor Conference Call on 2014-07-30

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
  • Please check this link on top games on facebook. Its really really very interesting. http://192.169.201.59/~daawncom/?p=2234
    Are you sure you want to
    Your message goes here
No Downloads

Views

Total Views
266
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
1
Comments
1
Likes
1

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Q2 2014 Bayer Continues Positive Business Development July 30, 2014 / Marijn Dekkers, CEO • Q2 2014 Investor Conference Call • Marijn DekkersPage 1
  • 2. Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. • Q2 2014 Investor Conference Call • Marijn DekkersPage 2
  • 3. Page 3 Q2 2014 – Operational and Strategic Progress  Strong organic top line growth, in particular in Life Sciences  Underlying EBITDA improvement negatively impacted by minus €160m FX effect  Business portfolio significantly strengthened  Merck & Co. OTC acquisition & sGC pharma collaboration signed  Divestiture of Interventional business signed  Full-year Group Guidance 2014 maintained • Q2 2014 Investor Conference Call • Marijn Dekkers
  • 4. Page 4 EBIT in € million +14% 1,473 1,287 Sales in € million % currency & portfolio adj. +6% 10,45810,360 EBITDA adjusted** in € million +1%* 2,2172,195 Core EPS in € * +8% if FX effect of -€160m is added back **before special items Q2’14Q2’13 Q2’14Q2’13 Q2’14Q2’13 Q2’14Q2’13 Q2 2014 – Earnings Performance Impacted By Significant Currency Headwind • Q2 2014 Investor Conference Call • Marijn Dekkers -1% 1.531.54
  • 5. Q2 2014 – Regional Performance: Growth Led by Emerging Markets Page 5 Africa & Middle East Eastern Europe Emerging Markets Emerging Markets¹ +8% Others² +7% USA +6% Western Europe +4% Group Sales by Region Group €10,458m; +6% ~1,100 +13% ~1,500 +7% ~400 +1% ~700 +8% ¹ Emerging economies include: Latin America, Asia w/o Japan, Australia, New Zealand, Africa and Middle East incl. Turkey, Eastern Europe ² Others = Japan, Australia, New Zealand, Canada ³ Emerging Asia = Asia w/o Japan, Australia, New Zealand In € million, ∆% yoy Fx adjusted 36% 11%32% 21% Latin America Emerging Asia³ • Q2 2014 Investor Conference Call • Marijn Dekkers
  • 6. Q2 2014 – Cash Flow And Net Debt Development Page 6 +€0.9bn 9.9GCF oFCF 1,705 Invest- ments 529 1,072 ∆ y-o-y +1% +4% NCF 1,601 +4% +5% March 31, 2014 June 30, 2014 9.1 Cash Flow Net Debt Development Cash Flow in € million, Net Debt in € billion • Q2 2014 Investor Conference Call • Marijn Dekkers
  • 7. Q2 2014 – HealthCare: Continued Dynamic Growth Page 7 *before special items Sales Earnings Pharma +5% (+10%) Consumer Health -4% (+1%) 36% HealthCare €4,845m; +1% (+6%) 2,9601,885 Price +1% Volume +5% Fx -6% Portfolio +1% In € million, ∆% yoy, () = Fx & portf. adjusted Q2‘13 Q2‘14 Q2‘13 Q2‘14 1,328 1,355 +2% 987 991 0% Adj. EBITDA* Adj. EBIT* • Q2 2014 Investor Conference Call • Marijn Dekkers () = Fx effect in € million (-120)
  • 8. Q2 2014 – Pharma: Launch Products Drive Growth Page 8 *before special items Sales Earnings Launch products Pharmaceuticals €2,960m; +5% (+10%) 702 In € million, ∆% yoy, () = Fx & portf. adjusted Q2‘13 Q2‘14 Q2‘13 Q2‘14 921 927 +1% 685 Adj. EBITDA* Adj. EBIT* 668 -2% • Q2 2014 Investor Conference Call • Marijn Dekkers () = Fx effect in € million (-100)
  • 9. Q2 2014 – Consumer Health: Strong Consumer Care and Animal Health Business Page 9 *before special items Sales Earnings Medical Care -9% (-5%) Consumer Care -2% (+4%) 36% Consumer Health €1,885m; -4% (+1%) 595 932 In € million, ∆% yoy, () = Fx & portf. adjusted Q2‘13 Q2‘14 Q2‘13 Q2‘14 407 428 +5% 302 +7%323 Adj. EBITDA* Adj. EBIT* • Q2 2014 Investor Conference Call • Marijn Dekkers Animal Health -1% (+5%) 358 () = Fx effect in € million (-20)
  • 10. Sales Earnings Q2 2014 – CropScience: Strong Performance in North / Latin America Page 10 Crop Protection +3% (+10%) Environmental Science +2% (+8%) Seeds +7% (+16%) In € million, ∆% yoy, () = Fx & portf. adjusted CropScience €2,470m; +3% (+11%) Price +3% Volume +8% Fx -7% Portfolio 0% 2,010 Q2‘13 Q2‘14 Q2‘13 Q2‘14 624 615 -1% 514 470 -9% Adj. EBITDA* Adj. EBIT* 197 263 • Q2 2014 Investor Conference Call • Marijn Dekkers *before special items () = Fx effect in € million (-40)
  • 11. Sales Earnings Q2 2014 – MaterialScience: Volumes Driven by Increased Demand Page 11 **CAS: Coatings, Adhesives, Specialties *** IO: Industrial Operations CAS** -2% (+4%) In € million, ∆% yoy, () = Fx & portf. adjusted *before special items MaterialScience €2,864m; 0% (+4%) Price -2% Volume +6% Fx -4% Portfolio 0% 1,532694 IO*** -10% (-9%) Q2‘13 Q2‘14 Q2‘13 Q2‘14 Adj. EBITDA* Adj. EBIT* 274 270 -2% 112 126 483 155 • Q2 2014 Investor Conference Call • Marijn Dekkers Polyurethanes -1% (+3%) Polycarbonates +5% (+8%) +13% () = Fx effect in € million (-10)
  • 12. Q2 2014 – Full-Year Group Guidance Maintained Page 12 2013 2014E (Avg. Fx rates Q4’13) 2014E (Spot Fx rates as of June 30, 2014 for 2H’14) Sales €40.2bn ~5% to ~€41-42bn (neg. FX effect approx. -2%) ~6% to ~€41bn (neg. FX effect approx. -4%) adj. EBITDA €8.4bn low- to mid-single- digit % increase (neg. FX effect approx. -5%) low- to mid-single- digit % increase (neg. FX effect approx. -6%) core EPS €5.61 mid-single-digit % increase (neg. FX effect approx. -6%) mid-single-digit % increase (neg. FX effect approx. -9%) Sales ∆ Fx and portfolio adjusted, EBITDA before special items Outlook depends on specific planning assumptions as detailed in the Annual Report • Q2 2014 Investor Conference Call • Marijn Dekkers
  • 13. Q2 2014 Bayer Continues Positive Business Development July 30, 2014 / Marijn Dekkers, CEO • Q2 2014 Investor Conference Call • Marijn DekkersPage 13